$BMGL

Basel Medical Group Ltd

CIK:0002004489|SEC Filings

Consolidated Statement of Profit or Loss	12 Months Ended
Consolidated Statement of Profit or Loss	Jun. 30, 2025 USD ($) $ / shares shares	Jun. 30, 2025 SGD ($) $ / shares shares	Jun. 30, 2024 SGD ($) $ / shares shares
Profit or loss [abstract]
Revenue	$ 8,900,027	$ 11,319,944	$ 10,050,923
Other income	866,580	1,102,203	461,029
Consumables, medical supplies and other related expenses	(1,986,201)	(2,526,250)	(2,248,136)
Employee benefit expenses	(5,030,217)	(6,397,933)	(3,638,942)
Depreciation expense	(928,633)	(1,181,128)	(528,727)
Rent expense	(110,917)	(141,075)	(3,180)
Other operating expense	(2,619,403)	(3,331,619)	(1,512,168)
Impairment loss on goodwill	(8,763,025)	(11,145,691)
Finance cost	(160,349)	(203,948)	(176,238)
(Loss)/Profit before tax	(9,832,138)	(12,505,497)	2,404,561
Income tax expense	328,165	417,393	(331,761)
(Loss)/Profit after tax	(9,503,974)	(12,088,104)	2,072,800
(Loss)/Profit for the year, representing total comprehensive income for the year	(9,503,974)	(12,088,104)	2,072,800
(Loss)/Profit attributable to:
Owners of the Company	(9,503,580)	(12,087,603)	2,072,800
Non-controlling interests	(394)	(501)
(Loss)/Profit for the year	$ (9,503,974)	$ (12,088,104)	$ 2,072,800
Basic \| (per share)	$ (0.506)	$ (0.643)	$ 0.13
Diluted \| (per share)	$ (0.506)	$ (0.643)	$ 0.13
Basic	18,785,750	18,785,750	16,250,000
Diluted	18,785,750	18,785,750	16,250,000

Consolidated Statement of Cash Flows	12 Months Ended
Consolidated Statement of Cash Flows	Jun. 30, 2025 USD ($)	Jun. 30, 2025 SGD ($)	Jun. 30, 2024 SGD ($)
Cash flows from operating activities
(Loss)/Profit before tax	$ (9,832,138)	$ (12,505,497)	$ 2,404,561
Adjustments for:
Bad debts written off	189,013	240,405
Reversal of estimated credit losses			(55,741)
Provision for estimated credit losses	(536,404)	(682,252)	50,168
Depreciation of property and equipment	84,644	107,659	30,093
Amortisation of right-of-use assets	843,989	1,073,469	498,635
Loss on written off fixed asset	138,549	176,220
Impairment loss on goodwill	8,763,025	11,145,691
Interest expense	160,349	203,948	176,238
Operating cash flows before changes in working capital	(188,973)	(240,357)	3,103,954
Changes in working capital:
Inventories	(239,218)	(304,261)	22,571
Trade and other receivables	(5,727,120)	(7,284,324)	(415,080)
Trade and other payables	3,409,904	4,337,057	387,690
Cash (used in)/ generated from operations	(2,745,407)	(3,491,885)	3,099,135
Interest paid	(509,704)	(648,292)	(176,238)
Income tax paid	(160,349)	(203,948)	(413,612)
Net cash (used in)/generated from operating activities	(3,415,460)	(4,344,125)	2,509,285
Cash flows from investing activities
Acquisition of property and equipment	(43,054)	(54,760)	(7,920)
Acquisition of new subsidiary	(8,637,578)	(10,986,135)
(Increase) in investment in associate	(39)	(49)
Cash provided by/ (used in) investing activities	(8,680,671)	(11,040,944)	(7,920)
Cash flows from financing activities
Deferred offering costs	1,223,544	1,556,226	(1,588,024)
Decrease in amount due from a director			1,320,457
Increase in amount due to related parties	260,405	331,209	1,311,390
Decrease/(Increase) in amount due from related parties	8,300,370	10,557,240	(73)
Increase in bank overdraft	48,251	61,371
Proceeds from borrowings	3,144,901	4,000,000
Payment of principal portion of lease liabilities	(771,556)	(981,342)	(566,039)
Repayment of borrowings	(6,495,235)	(8,261,290)	(2,356,930)
(Decrease)/Increase in amount due to former director	(87,632)	(111,459)	111,459
Non-controlling interest contributions	2,751	3,499
Share issuance	7,668,358	9,753,384
Net cash generated from/(used in) financing activities	13,294,157	16,908,838	(1,767,760)
Net increase/(decrease) in cash and cash equivalents	1,198,026	1,523,769	733,605
Cash and cash equivalents at beginning of financial period	1,533,967	1,951,053	1,217,448
Effects of currency translation on cash and cash equivalents	(389,763)	(495,739)
Cash and cash equivalents at end of financial year	$ 2,342,230	$ 2,979,083	$ 1,951,053

Consolidated Balance Sheets	Jun. 30, 2025 USD ($)	Jun. 30, 2025 SGD ($)	Jun. 30, 2024 SGD ($)
Non-current assets
Right-of-use-assets	$ 2,497,462	$ 3,176,522	$ 23,460
Property and equipment	218,183	277,507	34,513
Deferred tax assets	221,702	281,982	77,005
Investment in associate	39	49
Total Non-current assets	2,937,386	3,736,060	134,978
Current assets
Inventories	295,850	376,291	72,030
Trade and other receivables	7,651,065	9,731,390	2,005,219
Cash and cash equivalents	2,342,230	2,979,083	1,951,053
Deferred offering costs	25,000	31,798	1,588,024
Total Current assets	10,314,145	13,118,562	16,173,566
Total assets	13,251,531	16,854,622	16,308,544
Non-current liability
Borrowings	1,020,801	1,298,357	1,583,434
Current liabilities
Trade and other payables	5,435,180	6,913,006	2,575,949
Borrowings	1,667,677	2,121,119	2,706,356
Amount due to related parties	1,291,453	1,642,599	1,311,390
Amount due to a former director			111,459
Asset retirement obligation	11,795	15,000	15,000
Provision for income tax			443,315
Total liabilities	9,426,906	11,990,081	8,746,903
NET ASSETS	3,824,625	4,864,541	7,561,641
Capital attributable to equity holders of the Group
Share capital	25,609,109	34,208,562	24,455,178
Merger reserve arising from group restructuring	(18,362,500)	(24,455,170)	(24,455,170)
Retained earnings	(3,836,948)	(4,396,611)	7,561,633
Non-controlling interest	2,751	3,499
Translation reserve	412,213	(495,739)
Total equity	3,824,625	4,864,541	7,561,641
Total for all related parties [member]
Current assets
Amount due from related parties			$ 10,557,240